MDCX
Medicus Pharma Ltd.1.8000
-0.0300-1.64%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
44.48MP/E (TTM)
-Basic EPS (TTM)
-2.23Dividend Yield
0%Recent Filings
8-K
8-K
8-K
Medicus advances SkinJect, acquires Antev
Medicus Pharma advanced its SkinJect program for non-invasive basal cell carcinoma treatment, randomizing over 75% of 90 U.S. patients in Phase 2 study SKNJCT-003 by August 2025, while launching SKNJCT-004 in the UAE in October and securing UK regulatory approvals in November for expansion. The company completed its August 2025 acquisition of Antev, adding Teverelix, a GnRH antagonist targeting high-risk prostate cancer and urinary retention without testosterone surge risks. Cash rose to $8.7 million, but net loss widened to $16.0 million amid accelerated R&D. Pipeline bolsters oncology focus, yet clinical outcomes remain uncertain.
10-Q
Q3 FY2025 results
Medicus Pharma's Q3 FY2025 results show operating losses widening to $15.4M from $2.3M y/y, driven by an $8.7M IPR&D charge for the Antev acquisition closed August 29, 2025, for $2.97M cash and 1.6M shares, recognizing $8.7M IPR&D with no alternative future use. Total nine-month operating loss hit $26.6M, up from $7.6M y/y, as R&D expenses climbed 143% q/q on clinical trials while G&A rose 58% y/y from public company costs. Net loss reached $16.0M ($1.12/share) for the quarter, versus $2.3M ($0.24/share) last year, with the gap to operating loss tied to $0.4M fair-value changes on debentures and $0.2M SEPA losses. Cash grew to $8.7M from $4.2M year-start, fueled by $25.3M financing inflows against $16.2M operating outflows; free cash flow not disclosed in the 10-Q. Debentures stand at $6.8M maturing September 2026 at 8%, with SEPA availability up to $10M remaining. Integration risks with Antev could delay Teverelix development.
8-K
SEPA share sales completed
Medicus Pharma completed SEPA Advances totaling 1,088,048 common shares sold to Yorkville for $2,526,364 across September and October 2025, with prices ranging from $1.7961 to $2.7698 per share. The company used part of the proceeds to prepay a portion of its outstanding debenture with Yorkville. This unregistered issuance bolsters liquidity. Future sales remain possible under the agreement.
BHC
Bausch Health Companies Inc.
6.93+0.02
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CPMD
Cannapharmarx Inc.
0.00-0.00
CRMD
CorMedix Inc.
11.44+0.11
GSK
GSK plc
48.78-0.46
INCR
Intercure Ltd.
1.45+0.05
INM
InMed Pharmaceuticals Inc.
1.31+0.12
ITHUF
iAnthus Capital Holdings, Inc.
0.01-0.00
MDNAF
Medicenna Therapeutics Corp.
0.79+0.01
NSRX
Nasus Pharma Ltd.
6.80+0.00